Research on amantadine conducted by the team of prof. Konrad Rejdak are at the halfway point. "About 500 people in the most difficult pandemic period were consulted and sought medical help. It happened regardless of the clinical trial. We did it in the sense of the mission [...] We are glad that, under our care, the mortality rates among people at risk They are so small. I am asking experts who criticize the sense of conducting the study to take this aspect into account - we did it regardless of ABM funding, we helped patients and we will continue to do it "- comments the president of the Polish Neurological Society.
Prof. Konrad Rejdak comments on the halfway point of research into the use of amantadine in the treatment of COVID-19
Published Feb. 23, 2022 12:06
In an interview with professor Konrad Rejdak, president of the Polish Neurological Society and leader of the research entitled "The use of amantadine in the prevention of progression and treatment of Covid-19 symptoms in patients infected with the SARS-CoV-2 virus" at:
- Conclusions at the halfway point of the research by the team of prof. Rejdak. Descriptive data at this stage is not sufficient to carry out statistical analyzes. Based on the available data, the Medical Research Agency agreed to continue the study.
- Study completion date. It depends, inter alia, from the course of the pandemic. Study enrollment is open until April 15 (blinded phase).
- Commentary on the words of prof. Adam Barczyk from the Medical University of Silesia on "Silesian" research on amantadine.
- Differences between the research of prof. Barczyk and prof. Rejdak
- Assessment of the health ministry's decision to lift the restrictions. Prof. Rejdak said there was a clear trend to mitigate the pandemic. He stressed that vaccines remain an absolute tool for inhibiting the effects of coronavirus infection.
Topics
Ministerstwo Zdrowia / Polskie Towarzystwo Neurologiczne / Konrad Rejdak / ABM / COVID-19 / amantadyna
